Psoriatic arthritis (PsA) is one of the most important comorbidities in patients with psoriasis (PsO), with approximately one third of PsO patients developing arthritis over their whole lifetime [1]. The quality of life is worse among the patients with PsA than PsO alone [2]. The primary strategies using biological agents for psoriatic arthritis, including interleukin (IL) 23 inhibitors, IL-17 inhibitors, and tumour necrosis factor inhibitors (TNFi), have demonstrated similar improvements in musculoskeletal symptoms in PsA.
